Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16118720 | 0.87 | MEN1 (0.41) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL16118673 | 0.86 | MEN1 (0.46) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL23562951 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL21064425 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL17586314 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL14657570 | 0.81 | MEN1 (0.42) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL26388800 | 0.81 | KMT2A (0.42) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL21496342 | 0.81 | DGAT1 (0.40) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL29525421 | 0.80 | CA1 (0.38) | MEN1MAPK1KMT2ADPP8DPP9 | |
| SCHEMBL20243118 | 0.79 | MEN1 (0.41) | MEN1MAPK1KMT2ADPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4488271-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-01-08 | — | — | EP | disclosed |
| CN-118765278-A | Indazole compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2024-10-11 | — | — | CN | disclosed |
| EP-4442317-A2 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2024-10-09 | — | — | EP | disclosed |
| CN-114014844-B | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3971177-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114014844-A | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR1, ACVR1B | MEN1 1985/4885MAPK1 333/4885KMT2A 517/4885 |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | HPGDS, PTGIS, HPGD | MEN1 2939/4885MAPK1 2015/4885KMT2A 3715/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | MEN1 3622/4885MAPK1 2982/4885KMT2A 4680/4885 |
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | MEN1 2026/4885MAPK1 335/4885KMT2A 1539/4885 |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | HPGDS, HPGD, PTGS1 | MEN1 4597/4885MAPK1 2151/4885KMT2A 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.